Chemotherapy programs of the National Prostatic Cancer Project (NPCP)

J. D. Schmidt, W. W. Scott, R. Gibbons, D. E. Johnson, G. R. Prout, S. Loening, M. Soloway, J. B. deKernion, J. E. Pontes, N. H. Slack, G. P. Murphy

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Results of the first nationally randomized trial of the National Prostatic Cancer Project revealed a demonstrable advantage for chemotherapy in the management of advanced disease (Stage D in relapse from endocrine therapy). Both cyclophosphamide and 5-Fluorouracil showed improved activity over standard therapy. A second trial for patients previously irradiated, with less tolerance to myelosuppressive agents, revealed an advantage for estramustine phosphate and streptozotocin over standard therapy. Subsequently completed trials have revealed activity for prednimustine and imidazole carboxamide (DTIC). Trials currently underway for newly-diagnosed Stage D and for Stage D disease clinically stable to diethylstilbestrol (DES) show promising activity for DES combined with cyclophosphamide. Current trials with single agents in advanced disease are comparing methyl-CCNU and hydroxyurea with cyclophosphamide; another is evaluating estramustine phosphate and vincristine alone and in combination. The use of chemotherapy in earlier staged patients as adjuvants to definitive surgery or irradiation is underway in two clinical trials, where the effect of cyclophosphamide and estramustine phosphate as long-term therapies is compared with no additional treatment.

Original languageEnglish
Pages (from-to)1937-1946
Number of pages10
JournalCancer
Volume45
Issue number7 Suppl
StatePublished - Jun 13 1980
Externally publishedYes

Fingerprint

Estramustine
Prostatic Neoplasms
Cyclophosphamide
Drug Therapy
Diethylstilbestrol
Phosphates
Prednimustine
Semustine
Therapeutics
Dacarbazine
Vincristine
Streptozocin
Disease Management
Fluorouracil
Clinical Trials
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Schmidt, J. D., Scott, W. W., Gibbons, R., Johnson, D. E., Prout, G. R., Loening, S., ... Murphy, G. P. (1980). Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer, 45(7 Suppl), 1937-1946.

Chemotherapy programs of the National Prostatic Cancer Project (NPCP). / Schmidt, J. D.; Scott, W. W.; Gibbons, R.; Johnson, D. E.; Prout, G. R.; Loening, S.; Soloway, M.; deKernion, J. B.; Pontes, J. E.; Slack, N. H.; Murphy, G. P.

In: Cancer, Vol. 45, No. 7 Suppl, 13.06.1980, p. 1937-1946.

Research output: Contribution to journalArticle

Schmidt, JD, Scott, WW, Gibbons, R, Johnson, DE, Prout, GR, Loening, S, Soloway, M, deKernion, JB, Pontes, JE, Slack, NH & Murphy, GP 1980, 'Chemotherapy programs of the National Prostatic Cancer Project (NPCP)', Cancer, vol. 45, no. 7 Suppl, pp. 1937-1946.
Schmidt JD, Scott WW, Gibbons R, Johnson DE, Prout GR, Loening S et al. Chemotherapy programs of the National Prostatic Cancer Project (NPCP). Cancer. 1980 Jun 13;45(7 Suppl):1937-1946.
Schmidt, J. D. ; Scott, W. W. ; Gibbons, R. ; Johnson, D. E. ; Prout, G. R. ; Loening, S. ; Soloway, M. ; deKernion, J. B. ; Pontes, J. E. ; Slack, N. H. ; Murphy, G. P. / Chemotherapy programs of the National Prostatic Cancer Project (NPCP). In: Cancer. 1980 ; Vol. 45, No. 7 Suppl. pp. 1937-1946.
@article{23444358c9b44474bbf727d8e5f1c2b9,
title = "Chemotherapy programs of the National Prostatic Cancer Project (NPCP)",
abstract = "Results of the first nationally randomized trial of the National Prostatic Cancer Project revealed a demonstrable advantage for chemotherapy in the management of advanced disease (Stage D in relapse from endocrine therapy). Both cyclophosphamide and 5-Fluorouracil showed improved activity over standard therapy. A second trial for patients previously irradiated, with less tolerance to myelosuppressive agents, revealed an advantage for estramustine phosphate and streptozotocin over standard therapy. Subsequently completed trials have revealed activity for prednimustine and imidazole carboxamide (DTIC). Trials currently underway for newly-diagnosed Stage D and for Stage D disease clinically stable to diethylstilbestrol (DES) show promising activity for DES combined with cyclophosphamide. Current trials with single agents in advanced disease are comparing methyl-CCNU and hydroxyurea with cyclophosphamide; another is evaluating estramustine phosphate and vincristine alone and in combination. The use of chemotherapy in earlier staged patients as adjuvants to definitive surgery or irradiation is underway in two clinical trials, where the effect of cyclophosphamide and estramustine phosphate as long-term therapies is compared with no additional treatment.",
author = "Schmidt, {J. D.} and Scott, {W. W.} and R. Gibbons and Johnson, {D. E.} and Prout, {G. R.} and S. Loening and M. Soloway and deKernion, {J. B.} and Pontes, {J. E.} and Slack, {N. H.} and Murphy, {G. P.}",
year = "1980",
month = "6",
day = "13",
language = "English",
volume = "45",
pages = "1937--1946",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "7 Suppl",

}

TY - JOUR

T1 - Chemotherapy programs of the National Prostatic Cancer Project (NPCP)

AU - Schmidt, J. D.

AU - Scott, W. W.

AU - Gibbons, R.

AU - Johnson, D. E.

AU - Prout, G. R.

AU - Loening, S.

AU - Soloway, M.

AU - deKernion, J. B.

AU - Pontes, J. E.

AU - Slack, N. H.

AU - Murphy, G. P.

PY - 1980/6/13

Y1 - 1980/6/13

N2 - Results of the first nationally randomized trial of the National Prostatic Cancer Project revealed a demonstrable advantage for chemotherapy in the management of advanced disease (Stage D in relapse from endocrine therapy). Both cyclophosphamide and 5-Fluorouracil showed improved activity over standard therapy. A second trial for patients previously irradiated, with less tolerance to myelosuppressive agents, revealed an advantage for estramustine phosphate and streptozotocin over standard therapy. Subsequently completed trials have revealed activity for prednimustine and imidazole carboxamide (DTIC). Trials currently underway for newly-diagnosed Stage D and for Stage D disease clinically stable to diethylstilbestrol (DES) show promising activity for DES combined with cyclophosphamide. Current trials with single agents in advanced disease are comparing methyl-CCNU and hydroxyurea with cyclophosphamide; another is evaluating estramustine phosphate and vincristine alone and in combination. The use of chemotherapy in earlier staged patients as adjuvants to definitive surgery or irradiation is underway in two clinical trials, where the effect of cyclophosphamide and estramustine phosphate as long-term therapies is compared with no additional treatment.

AB - Results of the first nationally randomized trial of the National Prostatic Cancer Project revealed a demonstrable advantage for chemotherapy in the management of advanced disease (Stage D in relapse from endocrine therapy). Both cyclophosphamide and 5-Fluorouracil showed improved activity over standard therapy. A second trial for patients previously irradiated, with less tolerance to myelosuppressive agents, revealed an advantage for estramustine phosphate and streptozotocin over standard therapy. Subsequently completed trials have revealed activity for prednimustine and imidazole carboxamide (DTIC). Trials currently underway for newly-diagnosed Stage D and for Stage D disease clinically stable to diethylstilbestrol (DES) show promising activity for DES combined with cyclophosphamide. Current trials with single agents in advanced disease are comparing methyl-CCNU and hydroxyurea with cyclophosphamide; another is evaluating estramustine phosphate and vincristine alone and in combination. The use of chemotherapy in earlier staged patients as adjuvants to definitive surgery or irradiation is underway in two clinical trials, where the effect of cyclophosphamide and estramustine phosphate as long-term therapies is compared with no additional treatment.

UR - http://www.scopus.com/inward/record.url?scp=0018841963&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018841963&partnerID=8YFLogxK

M3 - Article

VL - 45

SP - 1937

EP - 1946

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 7 Suppl

ER -